siRNA-mediated STMN1 down-regulationis correlated with enhanced sensitivity of cancer cells to paclitaxelchemotherapy.296 These studies supportthe use of paclitaxel and siRNA to promote the antitumor activityof paclitaxel and to inhibit the resistance of cancer cells to paclitaxelchemotherapy.297 Future research in improvingthe antitumor activity of paclitaxel and siRNA should be directedat the use of nanotechnology. The gene discussed is STMN1; the disease is cancer.